Orofacial complications from immune checkpoint inhibitors: A retrospective analysis from two academic medical centers.

Autor: Al-Eryani K; Department of Orofacial Sciences, University of California, San Francisco, California, USA., Epstein JB; Dental Oncology Services, City of Hope Comprehensive Cancer Center, Duarte, California, USA.; Cedars Sinai Health System, Los Angeles, California, USA., Monreal AV; Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, California, USA., Villa A; Department of Orofacial Sciences, University of California, San Francisco, California, USA.; Oral Medicine, Oral Oncology and Dentistry, Miami Cancer Institute, Miami, Florida, USA.; Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA.
Jazyk: angličtina
Zdroj: Head & neck [Head Neck] 2024 Aug; Vol. 46 (8), pp. 1865-1872. Date of Electronic Publication: 2024 Jan 23.
DOI: 10.1002/hed.27646
Abstrakt: Background: Immune checkpoint inhibitors (ICIs) are FDA-approved for various cancers, yet their orofacial immune-related adverse events (irAEs) remain poorly understood. Our two-center retrospective study aims to better understand the prevalence and nature of these orofacial irAEs.
Methods: We retrospectively collected demographics, ICI details, and onset of orofacial irAEs in ICI-treated patients at University of California San Francisco and City of Hope (2013-2021). Orofacial irAEs were identified by ICD-10 codes and data categorized as dry mouth/xerostomia, oral mucosal lesions, and orofacial neuropathies. Patients with pre-existing orofacial conditions resembling the reported irAEs were excluded.
Results: Among 3768 ICI-treated patients, 408 (10.8%) developed 467 orofacial irAEs: oral mucosal diseases (41.4%), dry mouth/xerostomia (41.0%), and orofacial neuropathies (17.6%). Notably, head and neck cancers had the highest incidence of orofacial irAEs.
Conclusions: Orofacial irAEs are relatively common in patients receiving ICIs, necessitating careful monitoring and management of these complications during and after the treatment.
(© 2024 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: